Simultaneous determination of antidementia drugs in human plasma for therapeutic drug monitoring

Therapeutic Drug Monitoring

Volumn 33, Issue 2, 2011, Pages 227-238

  Noetzli, Muriel ^a   Choong, Eva ^a   Ansermot, Nicolas ^a   Eap, Chin B ^a,b,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b UNIVERSITY OF GENEVA   (Switzerland)

^c Hopital de Cery   (Switzerland)

Author keywords

donepezil; galantamine; LC MS; memantine; rivastigmine

Indexed keywords

3 HYDROXYBUPROPION; ACETONITRILE; AMFEBUTAMONE; AMMONIUM ACETATE; ANTIDEPRESSANT AGENT; DONEPEZIL; DRUG METABOLITE; GALANTAMINE; MEMANTINE; NAP 22690; NEUROLEPTIC AGENT; NOOTROPIC AGENT; PALIPERIDONE; RISPERIDONE; RIVASTIGMINE; UNCLASSIFIED DRUG;

ARTICLE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG STABILITY; ELUTION; HUMAN; ION MONITORING; MASS SPECTROMETRY; PH; PRIORITY JOURNAL; QUALITY CONTROL; REVERSED PHASE LIQUID CHROMATOGRAPHY; RISK REDUCTION; SOLID PHASE EXTRACTION;

CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, LIQUID; DEMENTIA; DRUG MONITORING; DRUG STABILITY; DRUG THERAPY, COMBINATION; HUMANS; MASS SPECTROMETRY; N-METHYLASPARTATE; PSYCHOTROPIC DRUGS; RECEPTORS, N-METHYL-D-ASPARTATE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION;

EID: 79953198916     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31821126cf     Document Type: Article

References (46)

1. Wilkinson DG, Francis PT, Schwam E, et al. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy. Drugs Aging. 2004;21: 453-478. (Pubitemid 38736890)
2. McKeage K. Spotlight on memantine in moderate to severe Alzheimer's disease. Drugs Aging. 2010;27:177-179.
3. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group concensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265. (Pubitemid 39587052)
4. Lanctot KL, Herrmann N, Yau KK, et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ. 2003;169:557-564. (Pubitemid 37174596)
5. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-1341. (Pubitemid 36384100)
6. Rockwood K, MacKnight C. Assessing the clinical importance of statistically significant improvement in anti-dementia drug trials. Neuroepidemiology. 2001;20:51-56. (Pubitemid 32453721)
7. Varsaldi F, Miglio G, Scordo MG, et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients. Eur J Clin Pharmacol. 2006; 62:721-726. (Pubitemid 44289502)
8. Spencer CM, Noble S. Rivastigmine. A review of its use in Alzheimer's disease. Drugs Aging. 1998;13:391-411. (Pubitemid 28523796)
9. Kornhuber J, Kennepohl EM, Bleich S, et al. Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet. 2007;46:599-612. (Pubitemid 47025360)
10. Tiseo PJ, Perdomo CA, Friedhoff LT. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br J Clin Pharmacol. 1998;46(Suppl 1):19-24. (Pubitemid 29197010)
11. Farlow MR. Clinical pharmacokinetics of galantamine. Clin Pharmacokinet. 2003;42:1383-1392. (Pubitemid 38045842)
12. Bachus R, Bickel U, Thomsen T, et al. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics. 1999;9:661-668. (Pubitemid 30011930)
13. Piotrovsky V, Van Peer A, Van Osselaer N, et al. Galantamine population pharmacokinetics in patients with Alzheimer's disease: modeling and simulations. J Clin Pharmacol. 2003;43:514-523. (Pubitemid 36506152)
14. Periclou A, Ventura D, Rao N, et al. Pharmacokinetic study of memantine in healthy and renally impaired subjects. Clin Pharmacol Ther. 2006;79: 134-143. (Pubitemid 43069584)
15. Fujita T, Urban TJ, Leabman MK, et al. Transport of drugs in the kidney by the human organic cation transporter, OCT2 and its genetic variants. J Pharm Sci. 2006;95:25-36.
16. Leabman MK, Huang CC, Kawamoto M, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics. 2002;12:395-405. (Pubitemid 34816419)
17. Lefevre G, Sedek G, Jhee SS, et al. Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients. Clin Pharmacol Ther. 2008;83:106-114.
18. Arlt S, Lindner R, Rosler A, et al. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging. 2008;25:1033-1047.
19. Hossain M, Jhee SS, Shiovitz T, et al. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Clin Pharmacokinet. 2002;41:225-234. (Pubitemid 34415840)
20. Leis HJ, Fauler G, Windischhofer W. Quantitative analysis of memantine in human plasma by gas chromatography/negative ion chemical ionization/mass spectrometry. J Mass Spectrom. 2002;37:477-480. (Pubitemid 34578389)
21. Shah HJ, Kundlik ML, Pandya A, et al. A rapid and specific approach for direct measurement of donepezil concentration in human plasma by LC-MS/MS employing solid-phase extraction. Biomed Chromatogr. 2008;.
22. Patel BN, Sharma N, Sanyal M, et al. Quantitation of donepezil and its active metabolite 6-O-desmethyl donepezil in human plasma by a selective and sensitive liquid chromatography-tandem mass spectrometric method. Anal Chim Acta. 2008;629:145-157.
23. Frankfort SV, Ouwehand M, van Maanen MJ, et al. A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226- 90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry. Rapid Commun Mass Spectrom. 2006;20:3330-3336. (Pubitemid 44763929)
24. Bhatt J, Subbaiah G, Kambli S, et al. A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. J Chromatogr B. 2007;852: 115-121. (Pubitemid 46830101)
25. Verhaeghe T, Diels L, de VR, et al. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the determination of galantamine in human heparinised plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;789:337-346. (Pubitemid 36549202)
26. Nirogi RV, Kandikere VN, Mudigonda K, et al. Quantitative determination of galantamine in human plasma by sensitive liquid chromatography- tandem mass spectrometry using loratadine as an internal standard. J Chromatogr Sci. 2007;45:97-103. (Pubitemid 46207398)
27. Almeida AA, Campos DR, Bernasconi G, et al. Determination of memantine in human plasma by liquid chromatography-electrospray tandem mass spectrometry: application to a bioequivalence study. J Chromatogr B. 2007;848:311-316. (Pubitemid 46453301)
28. Xie Z, Liao Q, Xu X, et al. Rapid and sensitive determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry: application to a pharmacokinetic study. Rapid Commun Mass Spectrom. 2006;20:3193-3198. (Pubitemid 44626781)
29. Pommier F, Frigola R. Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J Chromatogr B. 2003;784:301-313. (Pubitemid 36044013)
30. Apostolou C, Dotsikas Y, Kousoulos C, et al. Quantitative determination of donepezil in human plasma by liquid chromatography/tandem mass spectrometry employing an automated liquid-liquid extraction based on 96-well format plates. Application to a bioequivalence study. J Chromatogr B. 2007;848:239-244. (Pubitemid 46464046)
31. Liu MY, Meng SN, Wu HZ, et al. Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Clin Ther. 2008;30:641-653.
32. Yasui-Furukori N, Furuya R, Takahata T, et al. Determination of donepezil, an acetylcholinesterase inhibitor, in human plasma by highperformance liquid chromatography with ultraviolet absorbance detection. J Chromatogr B. 2002;768:261-265. (Pubitemid 34158861)
33. Malakova J, Nobilis M, Svoboda Z, et al. High-performance liquid chromatographic method with UV photodiode-array, fluorescence and mass spectrometric detection for simultaneous determination of galantamine and its phase I metabolites in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;853:265-274. (Pubitemid 46891366)
34. Hsieh YH, Yang YH, Yeh HH, et al. Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease. Electrophoresis. 2009;30:644-653.
35. Souverain S, Rudaz S, Veuthey JL. Matrix effect in LC-ESI-MS and LCAPCI- MS with off-line and on-line extraction procedures. J Chromatogr A. 2004;1058:61-66. (Pubitemid 39487204)
36. Xie W, Pawliszyn J, Mullett WM, et al. Comparison of solid-phase microextraction and liquid-liquid extraction in 96-well format for the determination of a drug compound in human plasma by liquid chromatography with tandem mass spectrometric detection. J Pharm Biomed Anal. 2007;45:599-608. (Pubitemid 350007951)
37. Bergeron A, Furtado M, Garofolo F. Importance of using highly pure internal standards for successful liquid chromatography/tandem mass spectrometric bioanalytical assays. Rapid Commun Mass Spectrom. 2009; 23:1287-1297.
38. Guidance for Industry: Bioanalytical Method Validation. FDA. 2001. Available at: www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM070107.pdf. Accessed September 2010.
39. Hubert P, Nguyen-Huu JJ, Boulanger B, et al. Validation of quantitative analytical procedure. Harmonization of approaches. STP Pharma Pract. 2003;13:101-138. (Pubitemid 36791125)
40. Draft guideline on validation of bioanalytical methods. EMEA. 2009. Available at: www.emea.europa.eu/pdfs/human/ewp/19221709en.pdf. Accessed September 2010.
41. Bonfiglio R, King RC, Olah TV, et al. The effects of sample preparation methods on the variability of the electrospray ionization response for model drug compounds. Rapid Commun Mass Spectrom. 1999;13: 1175-1185. (Pubitemid 29285118)
42. Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem. 2003;75:3019-3030. (Pubitemid 36830428)
43. Rogers SL, Cooper NM, Sukovaty R, et al. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol. 1998;46(Suppl 1):7-12. (Pubitemid 29197008)
44. Schappler J, Nicoli R, Nguyen DTT, et al. Coupling ultra high pressure liquid chromatography with single quadrupole mass spectrometry for the analysis of a complex drug mixture. Talanta. 2009;78:377-387.
45. Peng L, Farkas T. Analysis of basic compounds by reversed-phase liquid chromatography-electrospray mass spectrometry in high-pH mobile phases. J Chromatogr A. 2008;1179:131-144.
46. Wieling J. LC-MS-MS experiences with internal standards. Chromatographia Supplement. 2002;55:S-107-S-113.